Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 17/20 | 0.48 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5119304 | 0.84 | HTR2C (0.46) | BCHEHTR2CMCHR1SMN1; SMN2 | |
| SCHEMBL5129254 | 0.83 | ALDH1A1 (0.47) | SMN1; SMN2 | |
| SCHEMBL5121515 | 0.82 | HTR2C (0.47) | BCHEHTR2CMCHR1 | |
| SCHEMBL5116652 | 0.77 | GLA (0.58) | — | |
| SCHEMBL5129654 | 0.76 | MCHR1 (0.50) | HTR2CMCHR1SMN1; SMN2 | |
| SCHEMBL5117227 | 0.75 | THRB (0.46) | HTR2CMCHR1 | |
| SCHEMBL5129349 | 0.74 | KMT2A (0.52) | SMN1; SMN2 | |
| SCHEMBL5121610 | 0.74 | ERCC1 (0.43) | HTR2CMCHR1SMN1; SMN2 | |
| SCHEMBL5113424 | 0.74 | ERCC1 (0.46) | MCHR1SMN1; SMN2 | |
| SCHEMBL5130148 | 0.74 | ALDH1A1 (0.54) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050075356-A1 | Dihydroxypyrimidine carboxamide inhibitors of hiv integrase | ISTITUTO DI RICHERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2005-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075356-A1 | Dihydroxypyrimidine carboxamide inhibitors of hiv integrase | DUT, DPYD, TYMP | BCHE 1797/4885HTR2C 3504/4885MCHR1 4469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.